source
- Merck and Moderna report success in late-stage trial of personalized mRNA cancer vaccineMerck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be…
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpointMerck and Moderna reported that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence in a Phase 3 study. The interim analysis showed a statistically si…